Try our beta test site
150 studies found for:    "Neurotoxicity syndromes"
Show Display Options
Rank Status Study
1 Terminated A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
Condition: Neurotoxicity Syndromes
Intervention: Drug: Dextromethorphan
2 Recruiting To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity
Condition: Neurotoxicity Syndromes
Interventions: Other: Questionnaires;   Procedure: Peripheral nervous system examination;   Genetic: Whole Genome Sequence
3 Recruiting Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
Condition: Neurotoxicity
Intervention: Drug: monosialoganglioside
4 Terminated Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
Condition: Neurotoxicity
Intervention: Drug: Vitamin D3
5 Recruiting Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Condition: Neurotoxicity
Interventions: Drug: placebo;   Drug: GM;   Drug: oxaliplatin-based chemotherapy
6 Completed Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Conditions: Neurotoxic Disorders;   Cancer
Intervention: Drug: Mangafodipir
7 Completed
Has Results
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Conditions: Colorectal Cancer;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
8 Unknown  Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neurotoxicity
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
9 Withdrawn Scopolamine Treatment for Patients With Organophosphate Poisoning
Condition: Neurotoxicity Syndromes
Intervention: Drug: Placebo
10 Completed Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo;   Drug: oxaliplatin
11 Completed Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
Conditions: Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
12 Completed Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
Conditions: Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
13 Completed Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors
Conditions: Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
14 Completed Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201
Conditions: Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity
Intervention: Procedure: management of therapy complications
15 Completed Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel 80 mg/m2;   Drug: Nab-paclitaxel 100 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1, 8 and 15;   Drug: Nab-paclitaxel 150 mg/m2 days 1 and 15
16 Terminated Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
Condition: Primary Central Nervous System Lymphoma (PCNSL)
Intervention:
17 Completed Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Conditions: Metastases;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: Xaliproden (SR57746A);   Drug: Placebo;   Drug: Oxaliplatin;   Drug: 5-Fluorouracil;   Drug: Leucovorin
18 Recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC
Condition: Colorectal Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
19 Recruiting Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: monosialotetrahexosylganglioside Sodium;   Other: placebo
20 Completed
Has Results
Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
Conditions: Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: vitamin E;   Other: placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.